Skip to content
Research Article Open access CC BY 4.0

Overview on Juvenile Idiopathic Arthritis: A Review

Ahlam Shary J. Hazazi, Badaya Awadh M. Alshehri, Yara Abdulrahman Alali, Rahf Mohammed I. Alqarni, Ibtisam Shary J. Hazazi, Nujud Abdulqader Albalawi, Dimah Mohammed A. Abu Murad, Atheer Mansour E Alatawi, Nouf Ali Alatawi, Maisaa Mokhtar M. Yousuf

Journal of Pharmaceutical Research International · pp. 139–147 · Published 10 Aug 2021

10.9734/jpri/2021/v33i40B32273

Abstract

Juvenile idiopathic arthritis (JIA) is a broad term that refers to a clinically heterogeneous group of arthritis that develops before the age of 16 and has no recognized cause. JIA treatment has evolved during the last two decades. Clinical trials research has been directed at more specific therapeutics based on what has been discovered about the biology of disease. Pediatric rheumatologists now have many more medications to offer patients, with the expectation that their disease will be managed, thanks to advances in immune system research and the introduction of biologic drugs in the twenty-first century. Continuing development in these biological agents and discoveries new drugs as long as developing current gene analysis techniques is the best method to treat JIA and provide best quality of life.

Juvenile idiopathic arthritis oligoarthritis polyarthritis rheumatic disease

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.